Depomed, Inc., a specialty pharmaceutical company, focuses on developing products for pain and other conditions, and diseases of the central nervous system in the United States. The company primarily offers Gralise (gabapentin), an once-daily product for the management of postherpetic neuralgia; Zipsor (diclofenac potassium) liquid filled capsule, a non-steroidal anti-inflammatory drug for the treatment of mild to moderate acute pain in adults; and Glumetza, a metformin hydrochloride extended release tablets for use in adults with type 2 diabetes. It is also involved in the clinical development of two product candidates, comprising Serada, which completed Phase III clinical trials for the treatment of menopausal hot flashes; and DM-1992 that completed a Phase II trial for Parkinson's disease. The company sells its Gralise products to wholesalers and retail pharmacies. Depomed, Inc. has license and collaboration agreements with Santarus, Inc.; Covidien, Ltd.; Boehringer Ingelheim International GMBH; Ironwood Pharmaceuticals, Inc.; Merck & Co., Inc.; Janssen Pharmaceutica N.V.; Janssen Pharmaceuticals, Inc.; Abbott Products Inc.; Patheon Puerto Rico, Inc.; Valeant Pharmaceuticals International, Inc.; and PharmaNova, Inc. The company was founded in 1995 and is headquartered in Newark, California.
Market Trend Signal
Stock Analysis Software and Trading System